Please note that the details of this Challenge are no longer open. This challenge is awarded and is no longer accepting new submissions. You can:
Challenge Noninvasive Biomarkers for Liver Fibrosis
Noninvasive Biomarkers for Liver Fibrosis
STATUS: Awarded
Active Solvers: 628
Posted: Jun 17 2015
Challenge ID: 9933671
Team Project Rooms are available on this Challenge Team Share Challenge Share

Liver disease is a continuum of diseases from viral or toxic insults leading via fibrosis to late stage chronic liver disease. Currently, there are limited treatment options, and most clinical trials searching for cures have failed, partially due to lack of predictive biomarkers. The Seeker is searching for novel biomarkers that are amenable for regular monitoring in the hopes of improving patient compliance and facilitating the evaluation of therapeutic agents in clinical trials.

This Challenge requires only a written proposal.


Liver disease represents a worldwide unmet medical need. Although there are various causes, the danger is that the liver will become so damaged that it can no longer function adequately. Whether the insult is a viral infection, chemical injury, or immune-related, liver disease follows a slow and steady progression. Early stage liver disease is characterized by inflammation, which if left untreated, can cause scarring and fibrosis. A healthy liver is capable of repair and regeneration, but when there are architectural changes to the tissue, the damage can no longer be reversed. Biopsies are routinely conducted to diagnose liver fibrosis and cirrhosis. Undergoing this invasive procedure involves significant abdominal pain along with the risk for complications and sampling error. Therefore, many patients are reluctant to have a second biopsy even when it is medically advisable. The Seeker desires a specific and sensitive biomarker(s) that is highly associated with liver fibrosis and could be used as a surrogate for clinical efficacy and ideally, could guide treatment selection.

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 17, 2015. Late submissions will not be considered.

This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.

To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, as further described in the Challenge-Specific Agreement, Solvers will grant to the Seeker a one hundred and eighty (180)-day Exclusivity Period from the deadline [11:59 PM (US Eastern Time) on August 17, 2015] for a non-exclusive license to practice their solutions for review, analysis and testing of the Proposed Solutions, an option for the grant of a further non-exclusive license, and an exclusive option to negotiate in good faith the terms of an exclusive license.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is a Theoretical-Licensing Challenge?

An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.

This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.

Share This Challenge